Key clinical point: Low arginine bioavailability was associated with increased risk for severe fever with thrombocytopenia syndrome (SFTS) fatality.
Major finding: Arginine bioavailability had an area under the receiver operating curve of 0.713 for predicting fatality.
Study details: A prospective cohort metabolomics study of 242 serum samples from patients with and without SFTS and a randomized, double-blind, placebo-controlled clinical trial of 113 patients given intravenous arginine supplementation or vehicle alone, in conjunction with supportive care.
Disclosures: The study was partially funded by a Bayer Investigator Award; Dr. Li and coauthors reported no other conflicts of interest.
Li X-K et al. Sci Transl Med. doi: 10.1126/scitranslmed.aat4162.
This Week's Must Reads
Must Reads in Mixed Topics
Low arginine linked to SFTS, Li X-K et al. Sci Transl Med. doi: 10.1126/scitranslmed.aat4162
Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7
NHL Survivors Tend to Have Impaired Cognition, Cancer; ePub 2017 Sep 15; Ehrhardt, et al